Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?

Critical Reviews in Oncogenesis
Elizabeth R Lawlor, Poul H Sorensen

Abstract

Ewing sarcoma (ES) is a highly aggressive bone and soft-tissue tumor with peak incidence among adolescents and young adults. Despite advances in local control and systemic chemotherapy, metastatic relapse after an initial clinical remission remains a significant clinical problem. In addition, metastasis at the time of presentation or at relapse continues to be the leading cause of death for patients diagnosed with ES. Since the discovery of the pathognomonic EWS-FLI1 fusion gene more than 20 years ago, much about the molecular and cellular biology of ES pathogenesis has been learned. In addition, more recent exploitation of advances in stem cell and developmental biology has provided key insights into the cellular origins of ES and the role of epigenetic deregulation in tumor initiation and maintenance. Nevertheless, the mechanisms that drive tumor relapse and metastasis remain largely unknown. These gaps in our knowledge continue to hamper the development of novel therapeutic strategies that may improve outcomes for patients with relapsed and metastatic disease. In this article we review the current status of ES biology research, highlighting areas of investigation that we consider to have the greatest potential to yield findi...Continue Reading

Citations

Aug 28, 2016·The Journal of Surgical Research·Andrew J JacobsRichard D Glick
Aug 26, 2016·Indian Journal of Palliative Care·Ashish GuliaPankaj Kumar Panda
Aug 24, 2016·Expert Review of Molecular Diagnostics·Frederic G Barr
Aug 28, 2016·Neoplasia : an International Journal for Oncology Research·Kelly M BaileyElizabeth R Lawlor
Aug 18, 2017·Journal of Pediatric Hematology/oncology·Stefan SchifflersChristophe F Chantrain
Feb 2, 2018·Molecular & Cellular Proteomics : MCP·Allegra G HawkinsElizabeth R Lawlor
Sep 6, 2017·Pediatric Blood & Cancer·Sun ChooJing Yang
Apr 20, 2018·The Journal of Pathology·Laurie K SvobodaElizabeth R Lawlor
Jan 8, 2019·British Medical Bulletin·Sarah J Jones
Aug 17, 2016·Oncotarget·Melanie A KrookElizabeth R Lawlor
Jun 17, 2020·JCI Insight·Allegra G HawkinsElizabeth R Lawlor
Jan 11, 2017·Tissue Engineering. Part C, Methods·Aranzazu VillasanteGordana Vunjak-Novakovic
Feb 7, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·P GargalloA Cañete
May 4, 2016·Médecine sciences : M/S·Thomas G P GrünewaldOlivier Delattre
Sep 20, 2019·International Journal of Molecular Sciences·Angela GalardiAngela Di Giannatale
Oct 27, 2020·Journal of Cancer Research and Clinical Oncology·Bin PanKaijin Guo
Apr 14, 2017·Cancer Research·Toyoki YoshimotoTakuro Nakamura
Jan 10, 2021·Oncogenesis·Lisa BierbaumerHeinrich Kovar
Dec 10, 2020·The Journal of Biological Chemistry·Hyewon ParkMizuki Azuma
Oct 7, 2020·Molecular Cancer Research : MCR·Jeffrey C MartinJoyce E Ohm
Nov 17, 2020·Current Oncology Reports·Fiorela N Hernandez TejadaDouglas Harrison
Jul 31, 2021·Frontiers in Bioengineering and Biotechnology·Aranzazu VillasanteGordana Vunjak-Novakovic
Jul 8, 2021·Cell Reports·Panneerselvam JayabalYuzuru Shiio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

© 2021 Meta ULC. All rights reserved